{"id":"3ebbd5e5-f543-41c1-b447-8d0d51c720c1","slug":"prospective-comparative-study-of-intraoperative-balloon-electronic-brachytherapy-versus-resection-with-multidisciplinary-adjuvant-therapy-for-recurrent-glioblastoma","title":"Prospective comparative study of intraoperative balloon electronic brachytherapy versus resection with multidisciplinary adjuvant therapy for recurrent glioblastoma","authors":["Aleksey Krivoshapkin","Aleksey Gaytan","Orkhan Abdullaev","Nidal Salim","Gleb Sergeev","Ilya Marmazeev","Evaldas Cesnulis","Tim Killeen","Vladimir Tyuryn","Roman Kiselev","Pavel Syomin","Aldo Spallone"],"abstract":"Background: Intraoperative balloon electronic brachytherapy (IBEB) may provide potential benefit for local control of recurrent cerebral glioblastomas (GBMs). Methods: This is a preliminary report of an open-label, prospective, comparative cohort study conducted in two neurosurgical centers with ongoing follow-up. At recurrence, patients at one center (n = 15) underwent reresection with IBEB while, at the second center (n = 15), control subjects underwent re-resection with various accepted second-line adjuvant chemoradiotherapy options. A comparative analysis of overall survival (OS) and local progression-free survival (LPFS) following re-resection was performed. Exploratory subgroup analysis based on postoperative residual contrast-enhanced volume status was also done. Results: In the IBEB group, median LPFS after re-resection was significantly longer than in the control group (8.0 vs. 6.0 months; log rank χ2 = 4.93, P = 0.026, P 2 = 4.23, P = 0.04, P < 0.05). Conclusion: These hypothesis-generating results from a small cohort of subjects suggest putative clinical benefit in OS and LPFS associated with maximal safe re-resection of recurrent GBM with IBEB versus re-resection and standard adjuvant therapy, a hypothesis that deserves further testing in an appropriately powered clinical trial.","thumbnailUrl":"https://sni-digital-videos.s3.amazonaws.com/articles/3ebbd5e5-f543-41c1-b447-8d0d51c720c1/featured/hero-1781561951757.png","publishDate":"2021-10-11T00:00:00.000Z","doi":"10.25259/SNI_494_2021","categories":["Neuro-oncology","Original Article"],"fullTextUrl":"https://surgicalneurologyint.com/wp-content/uploads/2021/10/11166/SNI-12-517.pdf"}